CDC IC, RDIF inject €10m into Olmix

The investment by CDC IC and RDIF is part of a wider €15m funding plan, executed via a special purpose vehicle created with Olmix - the two investors will contribute €10m while the business itself will inject €5m from its balance sheet.

Olmix is aiming to expand its production facilities in St Petersburg to further strengthen its presence in the Russian and CIS markets. The company aims to generate €150m in revenues by the end of 2017.

Part of the French state's investment arm Caisse des Dépôts, CDC IC is dedicated to direct investments alongside sovereign funds and other large international institutional players.

It has been co-investing with Russian sovereign wealth fund RDIF for some time but, concurrently with the announcement of the Olmix deal, the two parties have declared an agreement to expand the scope of their partnership. While CDC IC and RDIF previously focused on larger tickets, they will now also look for smaller investment opportunities, with tickets of less than €20m.

Company
Established in 1995, Olmix produces natural algae products for nutrition and hygiene, as well as human, animal and plant health. It has offices in 25 countries from which it distributes its products in 100 markets.

People
CDC International Capital – Laurent Vigier (CEO).
Russian Direct Investment Fund – Kirill Dmitriev (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• France
• CEE
• Industrials
• Expansion
• France
• Russia